Jump to content

User:Mr. Ibrahem/Lurbinectedin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Lurbinectedin
Clinical data
Pronunciation/ˌlɜːrbɪˈnɛktɪdin/
LUR-bi-NEK-ti-deen
Trade namesZepzelca
Other namesPM-01183
AHFS/Drugs.comMonograph
MedlinePlusa620049
License data
Pregnancy
category
Routes of
administration		Intravenous
Drug classAlkylating agent[2]
Legal status
Legal status
Identifiers
  • [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
Chemical and physical data
FormulaC41H44N4O10S
Molar mass784.88 g·mol−1
3D model (JSmol)
  • CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
  • InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
  • Key:YDDMIZRDDREKEP-HWTBNCOESA-N

Lurbinectedin, sold under the brand name Zepzelca, is a medication used to treat small cell lung cancer (SCLC).[2] It is used when the disease has spread despite other treatments.[2] It is given by gradual injection into a vein.[2]

Common side effects include low white blood cells, low red blood cells, kidney problems, low platelets, nausea, muscle pain, shortness of breath, liver inflammation, and constipation.[2] Other side effects may include infertility.[2] Use in pregnancy may harm the baby.[2] It is an alkylating agent.[2] It works by interfering with DNA duplication required for cell division.[3]

Lurbinectedin was approved for medical use in the United States in 2020 and Australia in 2021.[4][1] In the United States 4 mg costs about 7,200 USD as of 2021.[5] As of 2021 it is not available in the United Kingdom or Europe.[6]

References

[edit]
  1. ^ a b c "Zepzelca". Therapeutic Goods Administration (TGA). 22 September 2021. Archived from the original on 30 September 2021. Retrieved 30 September 2021.
  2. ^ a b c d e f g h i j k l "Zepzelca- lurbinectedin injection, powder, lyophilized, for solution". DailyMed. 15 June 2020. Archived from the original on 24 January 2021. Retrieved 24 September 2020.
  3. ^ "Lurbinectedin". National Cancer Institute. Archived from the original on 16 May 2020. Retrieved 15 June 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Lurbinectedin Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 24 November 2021.
  5. ^ "Zepzelca Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 24 November 2021.
  6. ^ "Lurbinectedin". SPS - Specialist Pharmacy Service. 13 September 2016. Archived from the original on 8 December 2021. Retrieved 24 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Lurbinectedin&oldid=1235827647"